Warnings & Recalls for Victoza
Black Box Warning for Victoza
Victoza was shown to increase the occurrence of thyroid C-cell tumors in lab rats and may cause thyroid cancer in some patients. The FDA's Adverse Event Reporting System had received 25 claims of thyroid cancer from early 2010 to late 2011. If the patient has had
Medullary Thyroid Cancer or has a family history of the illness, then he or she should not take Victoza.
Other Warnings
- Victoza may increase the patient's chance of contracting pancreatitis. The patient should not use Victoza during active pancreatitis.
- Victoza may cause or worsen renal damage. Notify your physician if you have a history of kidney problems.
- If severe allergic reaction or anaphylaxis occurs, discontinue using Victoza and seek medical help immediately.
- Victoza is a pregnancy category class C drug and may be unsafe to take during pregnancy. Victoza has caused birth defects and stunted growth in pregnant lab rats.
Victoza Treatment and Use
What is Victoza?
Victoza | liraglutide is a glucagon-like peptide-1 (GLP) receptor agonist injection which is used to help stabilize high blood sugar levels in patients who suffer from type two diabetes. Victoza is used in combination with dietary changes and an exercise regimen to increase its effectiveness. It comes as an injectable pen with the ability to select desired dosage. Victoza is marketed by Novo Nordisk and was approved for U.S. use in 2010.
What does Victoza do?
Victoza works on the liver, pancreas, and gut to lower and regulate glucose levels in diabetes patients by releasing insulin into the bloodstream.
Dosage
Victoza is available as an 18 mg injectable pen which can be set to administer 0.6 mg, 1.2 mg, or 1.8 mg doses. The patient must first select the prescribed dose before self administering the medication subcutaneously, or beneath the skin. The initial dose is 0.6 mg once a day for the first week. During the second week, dosage should be increased to 1.2 mg once a day. If this dosage is not effective, then the patient may take 1.8 mg once a day.
Lawsuits & Legal Information for Victoza
Victoza Lawsuit Updates
CurrentMulti-District Litigation (7/25/2013): The Judicial Panel on Multidistrict Litigation held a hearing to hear an oral argument in Portland, Maine on the proposed consolidation of cases regarding diabetes drugs Victoza, Januvia and Byetta.Petitions (4/2013): The consumer advocacy group Public Citizen petitioned for a Victoza recall due to concerns of pancreatic cancer, thyroid cancer and other serious adverse side effects.
Future
Far PastApproval (1/25/2010): Victoza was first approved by the FDA on January 25, 2010.